- Anti-diabetic medication
Anti-diabetic medications treat diabetes mellitus by lowering glucose levels in the blood. With the exceptions of insulin, exenatide, and pramlintide, all are administered orally and are thus also called oral hypoglycemic agents or oral antihyperglycemic agents. There are different classes of anti-diabetic drugs, and their selection depends on the nature of the diabetes, age and situation of the person, as well as other factors.
Diabetes mellitus type 1 is a disease caused by the lack of insulin. Insulin must be used in Type I, which must be injected.
Diabetes mellitus type 2 is a disease of insulin resistance by cells. Treatments include (1) agents which increase the amount of insulin secreted by the pancreas, (2) agents which increase the sensitivity of target organs to insulin, and (3) agents which decrease the rate at which glucose is absorbed from the gastrointestinal tract.
Several groups of drugs, mostly given by mouth, are effective in Type II, often in combination. The therapeutic combination in Type II may include insulin, not necessarily because oral agents have failed completely, but in search of a desired combination of effects. The great advantage of injected insulin in Type II is that a well-educated patient can adjust the dose, or even take additional doses, when blood glucose levels measured by the patient, usually with a simple meter, as needed by the measured amount of sugar in the blood.
- 1 Insulin
- 2 Sensitizers
- 3 Secretagogues
- 4 Alpha-glucosidase inhibitors
- 5 Peptide analogs
- 6 Comparison
- 7 Alternative medicine
- 8 References
- 9 References
InsulinMain article: insulin
Insulin is usually given subcutaneously, either by injections or by an insulin pump. Research is underway of other routes of administration. In acute care settings, insulin may also be given intravenously. There are generally above four types of insulin, characterized by the rate which they are metabolized by the body.
Insulin sensitizers address the core problem in Type II diabetes—insulin resistance.
BiguanidesMain article: Biguanide
Biguanides reduce hepatic glucose output and increase uptake of glucose by the periphery, including skeletal muscle. Although it must be used with caution in patients with impaired liver or kidney function, metformin, a biguanide, has become the most commonly used agent for type 2 diabetes in children and teenagers. Amongst common diabetic drugs, metformin is the only widely used oral drug that does not cause weight gain.
Typical reduction in glycated hemoglobin (A1C) values for metformin is 1.5–2.0%.
- Metformin (Glucophage) may be the best choice for patients who also have heart failure, but it should be temporarily discontinued before any radiographic procedure involving intravenous iodinated contrast, as patients are at an increased risk of lactic acidosis.
- Phenformin (DBI) was used from 1960s through 1980s, but was withdrawn due to lactic acidosis risk.
- Buformin also was withdrawn due to lactic acidosis risk.
Metformin is usually the first-line medication used for treatment of type 2 diabetes. It is generally prescribed at initial diagnosis in conjunction with exercise and weight loss as opposed to in the past, where it was prescribed after diet and exercise had failed. Initial dosing is 500 mg once daily, then if need be increased to 500 mg twice daily up to 1000 mg twice daily. It is also available in combination with other oral diabetic medications. There is an extended release formulation available, but it is typically reserved for patients experiencing GI side effects.
ThiazolidinedionesMain article: Thiazolidinedione
Thiazolidinediones (TZDs), also known as "glitazones," bind to PPARγ, a type of nuclear regulatory protein involved in transcription of genes regulating glucose and fat metabolism. These PPARs act on peroxysome proliferator responsive elements (PPRE ). The PPREs influence insulin sensitive genes, which enhance production of mRNAs of insulin-dependent enzymes. The final result is better use of glucose by the cells.
Typical reductions in glycated hemoglobin (A1C) values are 1.5–2.0%. Some examples are:
- rosiglitazone (Avandia): the European Medicines Agency recommended in September 2010 that it be suspended from the EU market due to elevated cardiovascular risks.
- pioglitazone (Actos)
- troglitazone (Rezulin): used in 1990s, withdrawn due to hepatitis and liver damage risk
Multiple retrospective studies have resulted in a concern about rosiglitazone's safety, although it is established that the group, as a whole, has beneficial effects on diabetes. The greatest concern is an increase in the number of severe cardiac events in patients taking it. The ADOPT study showed initial therapy with drugs of this type may prevent the progression of disease, as did the DREAM trial.
Concerns about the safety of rosiglitazone arose when a retrospective meta-analysis was published in the New England Journal of Medicine. There have been a significant number of publications since then, and a Food and Drug Administration panel voted, with some controversy, 20:3 that available studies "supported a signal of harm," but voted 22:1 to keep the drug on the market. The meta-analysis was not supported by an interim analysis of the trial designed to evaluate the issue, and several other reports have failed to conclude the controversy. This weak evidence for adverse effects has reduced the use of rosiglitazone, despite its important and sustained effects on glycemic control. Safety studies are continuing.
In contrast, at least one large prospective study, PROactive 05, has shown that pioglitazone may decrease the overall incidence of cardiac events in people with type 2 diabetes who have already had a heart attack.
SulfonylureasMain article: Sulfonylurea
Sulfonylureas were the first widely used oral anti-hyperglycaemic medications. They are insulin secretagogues, triggering insulin release by inhibiting the KATP channel of the pancreatic beta cells. Eight types of these pills have been marketed in North America, but not all remain available. The "second-generation" drugs are now more commonly used. They are more effective than first-generation drugs and have fewer side effects. All may cause weight gain.
Sulfonylureas bind strongly to plasma proteins. Sulfonylureas are only useful in Type II diabetes, as they work by stimulating endogenous release of insulin. They work best with patients over 40 years old, who have had diabetes mellitus for under ten years. They can not be used with type I diabetes, or diabetes of pregnancy. They can be safely used with metformin or -glitazones. The primary side effect is hypoglycemia.
Typical reductions in glycated hemoglobin (A1C) values for second generation sulfonylureas are 1.0–2.0%.
- First-generation agents
- tolbutamide (Orinase)
- acetohexamide (Dymelor)
- tolazamide (Tolinase)
- chlorpropamide (Diabinese)
- Second-generation agents
- glipizide (Glucotrol)
- glyburide (Diabeta, Micronase, Glynase)
- glimepiride (Amaryl)
- gliclazide (Diamicron)
MeglitinidesMain article: Meglitinide
Meglitinides help the pancreas produce insulin and are often called "short-acting secretagogues." They act on the same potassium channels as sulfonylureas, but at a different binding site. By closing the potassium channels of the pancreatic beta cells, they open the calcium channels, hence enhancing insulin secretion.
They are taken with or shortly before meals to boost the insulin response to each meal. If a meal is skipped, the medication is also skipped.
Typical reductions in glycated hemoglobin (A1C) values are 0.5–1.0%.
- repaglinide (Prandin)
- nateglinide (Starlix)
Adverse reactions include weight gain and hypoglycemia.
Alpha-glucosidase inhibitorsMain article: Alpha-glucosidase inhibitor
Alpha-glucosidase inhibitors are "diabetes pills" but not technically hypoglycemic agents because they do not have a direct effect on insulin secretion or sensitivity. These agents slow the digestion of starch in the small intestine, so that glucose from the starch of a meal enters the bloodstream more slowly, and can be matched more effectively by an impaired insulin response or sensitivity. These agents are effective by themselves only in the earliest stages of impaired glucose tolerance, but can be helpful in combination with other agents in type 2 diabetes.
Typical reductions in glycated hemoglobin (A1C) values are 0.5–1.0%.
These medications are rarely used in the United States because of the severity of their side effects (flatulence and bloating). They are more commonly prescribed in Europe. They do have the potential to cause weight loss by lowering the amount of sugar metabolized.
Research has shown the culinary mushroom maitake (Grifola frondosa) has a hypoglycemic effect, possibly due to the mushroom acting as a natural alpha glucosidase inhibitor.
Injectable Incretin mimetics
Incretins are insulin secretagogues. The two main candidate molecules that fulfill criteria for being an incretin are glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (glucose-dependent insulinotropic peptide, GIP). Both GLP-1 and GIP are rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4).
Injectable Glucagon-like peptide analogs and agonists
Glucagon-like peptide (GLP) agonists bind to a membrane GLP receptor. As a consequence, insulin release from the pancreatic beta cells is increased. Endogenous GLP has a half life of only a few minutes, thus an analogue of GLP would not be practical.
- Exenatide (also Exendin-4, marketed as Byetta) is the first GLP-1 agonist approved for the treatment of type 2 diabetes. Exenatide is not an analogue of GLP, but rather a GLP agonist. Exenatide has only 53% homology with GLP, which increases its resistance to degradation by DPP-4 and extends its half-life. Typical reductions in A1C values are 0.5–1.0%.
- Liraglutide, a once daily human analogue (97% homology), has been developed by Novo Nordisk under the brand name Victoza. The product was approved by the European Medicines Agency (EMEA) on July 3, 2009, and by the U.S. Food and Drug Administration (FDA) on January 25, 2010.
- Taspoglutide is presently in Phase III clinical trials with Hoffman-La Roche.
These agents may also cause a decrease in gastric motility, responsible for the common side effect of nausea, and is probably the mechanism by which weight loss occurs.
Gastric inhibitory peptide analogs
- None are FDA approved
Injectable peptide analogsMain article: Dipeptidyl peptidase-4 inhibitors
GLP-1 analogs resulted in weight loss and had more gastrointestinal side effects, while DPP-4 inhibitors were generally weight neutral and increased risk for infection and headache, but both classes appear to present an alternative to other antidiabetic drugs. However, weight gain and/or hypoglycaemia have been observed when DPP-4 inhibitors were used with sulfonylureas; effect on long-term health and morbidity rates are still unknown.
Dipeptidyl peptidase-4 (DPP-4) inhibitors increase blood concentration of the incretin GLP-1 by inhibiting its degradation by dipeptidyl peptidase-4.
- vildagliptin (Galvus) EU Approved 2008
- sitagliptin (Januvia) FDA approved Oct 2006
- saxagliptin (Onglyza) FDA Approved July 2009
- linagliptin (Tradjenta) FDA Approved May 2, 2011
DPP-4 inhibitors lowered hemoglobin A1C values by 0.74%, comparable to other antidiabetic drugs.
In one RCT comprising 206 patients aged 65 or older (mean baseline HgbA1c of 7.8%) receiving either 50 or 100 mg/d of Sitagliptin was shown to reduce HbA1c by 0.7% (combined result of both doses). A combined result of 5 RCTs enlisting a total of 279 patients aged 65 or older (mean baseline HbA1c of 8%) receiving 5 mg/d of Saxagliptin was shown to reduce HbA1c by 0.73%. A combined result of 5 RCTs enlisting a total of 238 patients aged 65 or older (mean baseline HbA1c of 8.6%) receiving 100 mg/d of Vildagliptin was shown to reduce HbA1c by 1.2%. Another set of 6 combined RCTs involving Alogliptin (not yet approved, might be released in 2012) was shown to reduce HbA1c by 0.73% in 455 patients aged 65 or older who received 12.5 or 25 mg/d of the medication.
Injectable Amylin analogues
Amylin agonist analogues slow gastric emptying and suppress glucagon. They have all the incretins actions except stimulation of insulin secretion. As of 2007[update], pramlintide is the only clinically available amylin analogue. Like insulin, it is administered by subcutaneous injection. The most frequent and severe adverse effect of pramlintide is nausea, which occurs mostly at the beginning of treatment and gradually reduces. Typical reductions in A1C values are 0.5–1.0%.
The following table compares some common anti-diabetic agents, generalizing classes although there may be substantial variation in individual drugs of each class:
Agent Mechanism Site of action Main advantages Main side effects Sulfonylureas Stimulating insulin production by inhibiting the KATP channel Pancreatic beta cells
Metformin Decreases insulin resistance Liver
- May result in mild weight loss
- Does not cause hypoglycemia
- GI symptoms, including diarrhea, nausea, abdominal pain
- Lactic acidosis
- Metallic taste
Acarbose Reduces intestinal glucose absorption GI tract
- Low risk
- GI symptoms, including diarrhea, abdominal cramping, flatulence
Thiazolidinediones Reduce insulin resistance by activating PPAR-γ Fat, muscle Hepatoxicity
Most anti-diabetic agents are contraindicated in pregnancy, in which insulin is preferred.
A number of medicinal plants have been studied for the treatment of diabetes however there is insufficient evidence to determine their effectiveness. Cinnamon has blood sugar lowering properties however whether or not it is useful for treating diabetes is unknown. While chromium supplements have no beneficial effect on healthy people, there might be an improvement in glucose metabolism in those with diabetics, although the evidence for this effect remains weak. Vanadyl sulfate, a salt of vanadium, is still in preliminary studies. There is tentative research that thiamine may prevent some diabetic complications however more research is needed.
- ^ Eurich; McAlister, FA; Blackburn, DF; Majumdar, SR; Tsuyuki, RT; Varney, J; Johnson, JA (2007). "Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review.". BMJ (Clinical research ed.) 335 (7618): 497. doi:10.1136/bmj.39314.620174.80. PMC 1971204. PMID 17761999. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1971204.
- ^ Fimognari; Pastorelli, R; Incalzi, RA (2006). "Phenformin-induced lactic acidosis in an older diabetic patient: a recurrent drama (phenformin and lactic acidosis).". Diabetes care 29 (4): 950–1. doi:10.2337/diacare.29.04.06.dc06-0012. PMID 16567854. http://care.diabetesjournals.org/cgi/pmidlookup?view=long&pmid=16567854.
- ^ Verdonck; Sangster, B; Van Heijst, AN; De Groot, G; Maes, RA (1981). "Buformin concentrations in a case of fatal lactic acidosis.". Diabetologia 20 (1): 45–6. doi:10.1007/BF01789112. PMID 7202882.
- ^ Hinterthuer, Adam (2008). "Retired Drugs: Failed Blockbusters, Homicidal Tampering, Fatal Oversights". Wired News. http://www.wired.com/medtech/drugs/multimedia/2008/10/gallery_retired_drugs?slide=6&slideView=6. Retrieved 2009-06-21.
- ^ Haffner, Steven M. (2007). "Expert Column – A Diabetes Outcome Progression Trial (ADOPT)". Medscape. http://www.medscape.com/viewarticle/552484. Retrieved 2007-09-21.
- ^ Gagnon, Louise (2007). "DREAM: Rosiglitazone Effective in Preventing Diabetes". Medscape. http://www.medscape.com/viewarticle/546503. Retrieved 2007-09-21.
- ^ Nissen; Wolski, K (2007). "Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.". The New England journal of medicine 356 (24): 2457–71. doi:10.1056/NEJMoa072761. PMID 17517853. Lay summary – Associated Press (May 21, 2007).
- ^ Wood, Shelley (2007-07-31). "FDA Advisory Panels Acknowledge Signal of Risk With Rosiglitazone, but Stop Short of Recommending Its Withdrawal". Heartwire. http://www.medscape.com/viewarticle/560709. Retrieved 2007-09-21.
- ^ Ajjan; Grant, PJ (2008). "The cardiovascular safety of rosiglitazone.". Expert opinion on drug safety 7 (4): 367–76. doi:10.1517/147403188.8.131.527. PMID 18613801.
- ^ Erdmann; Dormandy, JA; Charbonnel, B; Massi-Benedetti, M; Moules, IK; Skene, AM; Proactive, Investigators (2007). "The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.". Journal of the American College of Cardiology 49 (17): 1772–80. doi:10.1016/j.jacc.2006.12.048. PMID 17466227.
- ^ Rendell (2004). "Advances in diabetes for the millennium: drug therapy of type 2 diabetes.". MedGenMed : Medscape general medicine 6 (3 Suppl): 9. PMC 1474831. PMID 15647714. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1474831.
- ^ a b "Helping the pancreas produce insulin". HealthValue. http://www.healthvalue.net/diabetespancreasbeta.html. Retrieved 2007-09-21.
- ^ Konno; Tortorelis, DG; Fullerton, SA; Samadi, AA; Hettiarachchi, J; Tazaki, H (2001). "A possible hypoglycaemic effect of maitake mushroom on type 2 diabetic patients.". Diabetic Medicine 18 (12): 1010. doi:10.1046/j.1464-5491.2001.00532-5.x. PMID 11903406.
- ^ Hong; Xun, M; Wutong, W (2007). "Anti-diabetic effect of an alpha-glucan from fruit body of maitake (Grifola frondosa) on KK-Ay mice.". The Journal of pharmacy and pharmacology 59 (4): 575–82. doi:10.1211/jpp.59.4.0013. PMID 17430642.
- ^ Kubo; Aoki, H; Nanba, H (1994). "Anti-diabetic activity present in the fruit body of Grifola frondosa (Maitake). I.". Biological & pharmaceutical bulletin 17 (8): 1106–10. doi:10.1248/bpb.17.1106. PMID 7820117.
- ^ Lo, HC; Hsu, TH; Chen, CY (2008). "Submerged culture mycelium and broth of Grifola frondosa improve glycemic responses in diabetic rats.". The American journal of Chinese medicine 36 (2): 265–85. doi:10.1142/S0192415X0800576X. PMID 18457360.
- ^ Manohar; Talpur, NA; Echard, BW; Lieberman, S; Preuss, HG (2002). "Effects of a water-soluble extract of maitake mushroom on circulating glucose/insulin concentrations in KK mice.". Diabetes, obesity & metabolism 4 (1): 43–8. doi:10.1046/j.1463-1326.2002.00180.x. PMID 11874441.
- ^ Horio; Ohtsuru, M (2001). "Maitake (Grifola frondosa) improve glucose tolerance of experimental diabetic rats.". Journal of nutritional science and vitaminology 47 (1): 57–63. doi:10.3177/jnsv.47.57. PMID 11349892.
- ^ Matsuur; Asakawa, C; Kurimoto, M; Mizutani, J (2002). "Alpha-glucosidase inhibitor from the seeds of balsam pear (Momordica charantia) and the fruit bodies of Grifola frondosa.". Bioscience, biotechnology, and biochemistry 66 (7): 1576–8. doi:10.1271/bbb.66.1576. PMID 12224646.
- ^ Briones; Bajaj, M (2006). "Exenatide: a GLP-1 receptor agonist as novel therapy for type 2 diabetes mellitus.". Expert opinion on pharmacotherapy 7 (8): 1055–64. doi:10.1517/146565184.108.40.2065. PMID 16722815.
- ^ Gallwitz (2006). "Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.". International journal of clinical practice 60 (12): 1654–61. doi:10.1111/j.1742-1241.2006.01196.x. PMID 17109672.
- ^ Cvetković; Plosker, GL (2007). "Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).". Drugs 67 (6): 935–54. doi:10.2165/00003495-200767060-00008. PMID 17428109.
- ^ http://www.drugs.com/nda/liraglutide_080530.html May 2008
- ^ http://www.medicalnewstoday.com/articles/74913.php "Liraglutide Provides Significantly Better Glucose Control Than Insulin Glargine In Phase 3 Study" June 2007
- ^ http://www.medicalnewstoday.com/articles/110349.php "Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, And Blood Pressure In Patients With Type 2 Diabetes" June 2008
- ^ http://www.drugdevelopment-technology.com/projects/liraglutide/
- ^ http://www.novonordisk.com/science/about_rd/quarterly_rd_update.asp Oct 2008 Inc results of LEAD 6 extension
- ^ http://money.cnn.com/news/newsfeeds/articles/marketwire/0580389.htm January 2009
- ^ National Prescribing Service (August 1, 2010). "Dipeptidyl peptidase-4 inhibitors ('gliptins') for type 2 diabetes mellitus". RADAR. http://www.nps.org.au/health_professionals/publications/nps_radar/2008/august_2008/gliptins.
- ^ Amori RE, Lau J, Pittas AG (2007). "Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis". JAMA 298 (2): 194–206. doi:10.1001/jama.298.2.194. PMID 17622601. http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=17622601.
- ^ Barzilei, N; Mahoney EM, Guo H (2009). "Sitagliptin is well tolerated and leads to rapid improvement in blood glucose in the first days of monotherapy in patients aged 65 years and older with T2DM". Diabetes 58: 587.
- ^ Doucet, J; Chacra, A, Maheux, P, Lu, J, Harris, S, Rosenstock, J (2011 Apr). "Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus.". Current medical research and opinion 27 (4): 863–9. PMID 21323504.
- ^ Pratley, RE; Rosenstock, J, Pi-Sunyer, FX, Banerji, MA, Schweizer, A, Couturier, A, Dejager, S (2007 Dec). "Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy.". Diabetes care 30 (12): 3017–22. doi:10.2337/dc07-1188. PMID 17878242.
- ^ Pratley, RE; McCall, T, Fleck, PR, Wilson, CA, Mekki, Q (2009 Nov). "Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies.". Journal of the American Geriatrics Society 57 (11): 2011–9. PMID 19793357.
- ^ a b Table entries taken from page 185 in: Elizabeth D Agabegi; Agabegi, Steven S. (2008). Step-Up to Medicine (Step-Up Series). Hagerstwon, MD: Lippincott Williams & Wilkins. ISBN 0-7817-7153-6.
- ^ Yeh, GY; Eisenberg, DM, Kaptchuk, TJ, Phillips, RS (2003 Apr). "Systematic review of herbs and dietary supplements for glycemic control in diabetes.". Diabetes care 26 (4): 1277–94. doi:10.2337/diacare.26.4.1277. PMID 12663610.
- ^ Kirkham, S; Akilen, R, Sharma, S, Tsiami, A (2009 Dec). "The potential of cinnamon to reduce blood glucose levels in patients with type 2 diabetes and insulin resistance.". Diabetes, obesity & metabolism 11 (12): 1100–13. PMID 19930003.
- ^ Balk, EM; Tatsioni, A; Lichtenstein, AH; Lau, J; Pittas, AG (2007). "Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials". Diabetes care 30 (8): 2154–63. doi:10.2337/dc06-0996. PMID 17519436.
- ^ Thompson, KH; Lichter, J, LeBel, C, Scaife, MC, McNeill, JH, Orvig, C (2009 Apr). "Vanadium treatment of type 2 diabetes: a view to the future.". Journal of inorganic biochemistry 103 (4): 554–8. doi:10.1016/j.jinorgbio.2008.12.003. PMID 19162329.
- ^ Thornalley, PJ (2005 Aug). "The potential role of thiamine (vitamin B1) in diabetic complications.". Current diabetes reviews 1 (3): 287–98. doi:10.2174/157339905774574383. PMID 18220605.
- Lebovitz, Harold E. (2004). Therapy For Diabetes Mellitus and Related Disorders (4th ed.). Alexandria, VA: American Diabetes Association. ISBN 1-58040-187-2.
- Adams, Michael Ian; Holland, Norman Norwood (2003). Core Concepts in Pharmacology. Englewood Cliffs, NJ: Prentice Hall. ISBN 0-13-089329-3.
Oral anti-diabetic drugs and Insulin analogs (A10) InsulinMetformin# • Buformin‡ • Phenformin‡Aleglitazar† • Muraglitazar§ • Tesaglitazar§K+ ATPMeglitinides/"glinides"GLP-1 analogsExenatide • Liraglutide • Taspoglutide† • Albiglutide† • LixisenatideAnalogs/other insulinsfast-acting (Insulin lispro • Insulin aspart • Insulin glulisine) • short-acting (Regular insulin) • long-acting (Insulin glargine • Insulin detemir • NPH insulin) • ultra-long-acting (Insulin degludec†) • inhalable Exubera‡ OtherAmylin analogSGLT2 inhibitorsCanagliflozin† • Dapagliflozin† • Remogliflozin§ • Sergliflozin§OtherBenfluorex‡ • Tolrestat‡#WHO-EM. ‡Withdrawn from market. Clinical trials: †Phase III. §Never to phase III Diabetes (E10–E14, 250) Types of diabetesPrediabetes (Impaired fasting glucose, Impaired glucose tolerance) Blood testsBlood sugar · Glycosylated hemoglobin · Glucose tolerance test · Fructosamine Diabetes managementDiabetic diet · Anti-diabetic drugs · Insulin therapy · Glossary of diabetes Complications/prognosisDiabetic comas (Diabetic hypoglycemia, Diabetic ketoacidosis, Nonketotic hyperosmolar) · Diabetic angiopathy · Diabetic foot (ulcer, neuropathic arthropathy) · Diabetic myonecrosis · Diabetic nephropathy · Diabetic neuropathy · Diabetic retinopathy · Diabetic cardiomyopathy · Diabetic dermadrome (Diabetic dermopathy, Diabetic bulla, Diabetic cheiroarthropathy, Neuropathic ulcer) Lines of researchCategories:
- Anti-diabetic drugs
Wikimedia Foundation. 2010.